File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Comparative reactogenicity of enhanced influenza vaccines in older adults

TitleComparative reactogenicity of enhanced influenza vaccines in older adults
Authors
Keywordsinfluenza
vaccination
reactogenicity
Issue Date2020
PublisherOxford University Press. The Journal's web site is located at http://jid.oxfordjournals.org
Citation
The Journal of Infectious Diseases, 2020, Epub 2020-05-14 How to Cite?
AbstractBackground: We analyzed data from a randomized controlled trial on the reactogenicity of 3 enhanced influenza vaccines compared with standard-dose (SD) inactivated influenza vaccine. Methods: We enrolled community-dwelling older adults in Hong Kong, and we randomly allocated them to receive 2017–2018 northern hemisphere formulations of SD vaccine (FluQuadri; Sanofi Pasteur), MF59-adjuvanted vaccine (FLUAD; Seqirus), high-dose (HD) vaccine (Fluzone High-Dose; Sanofi Pasteur), or recombinant hemagglutinin vaccine (Flublok; Sanofi Pasteur). Local and systemic reactions were evaluated at days 1, 3, 7, and 14 after vaccination. Results: Reported reactions were generally mild and short-lived. Systemic reactions occurred in similar proportions of participants by vaccine. Some local reactions were slightly more frequently reported among recipients of the MF59-adjuvanted and HD vaccines than among SD vaccine recipients. Participants reporting feverishness 1 day after vaccination had mean fold rises in postvaccination hemagglutination inhibition titers that were 1.85-fold higher (95% confidence interval, 1.01–3.38) for A(H1N1) than in those who did not report feverishness. Conclusions: Some acute local reactions were more frequent after vaccination with MF59-adjuvanted and HD influenza vaccines, compared with SD inactivated influenza vaccine, whereas systemic symptoms occurred at similar frequencies in all groups. The association between feverishness and immunogenicity should be further investigated in a larger population. Clinical Trials Registration: NCT03330132.
Persistent Identifierhttp://hdl.handle.net/10722/283688
ISSN
2019 Impact Factor: 5.022
2015 SCImago Journal Rankings: 4.000

 

DC FieldValueLanguage
dc.contributor.authorCowling, BJ-
dc.contributor.authorThompson, MG-
dc.contributor.authorNg, TWY-
dc.contributor.authorFang, VJ-
dc.contributor.authorPerera, RAPM-
dc.contributor.authorLeung, NHL-
dc.contributor.authorChen, Y-
dc.contributor.authorSo, HC-
dc.contributor.authorIp, DKM-
dc.contributor.authorIuliano, AD-
dc.date.accessioned2020-07-03T08:22:43Z-
dc.date.available2020-07-03T08:22:43Z-
dc.date.issued2020-
dc.identifier.citationThe Journal of Infectious Diseases, 2020, Epub 2020-05-14-
dc.identifier.issn0022-1899-
dc.identifier.urihttp://hdl.handle.net/10722/283688-
dc.description.abstractBackground: We analyzed data from a randomized controlled trial on the reactogenicity of 3 enhanced influenza vaccines compared with standard-dose (SD) inactivated influenza vaccine. Methods: We enrolled community-dwelling older adults in Hong Kong, and we randomly allocated them to receive 2017–2018 northern hemisphere formulations of SD vaccine (FluQuadri; Sanofi Pasteur), MF59-adjuvanted vaccine (FLUAD; Seqirus), high-dose (HD) vaccine (Fluzone High-Dose; Sanofi Pasteur), or recombinant hemagglutinin vaccine (Flublok; Sanofi Pasteur). Local and systemic reactions were evaluated at days 1, 3, 7, and 14 after vaccination. Results: Reported reactions were generally mild and short-lived. Systemic reactions occurred in similar proportions of participants by vaccine. Some local reactions were slightly more frequently reported among recipients of the MF59-adjuvanted and HD vaccines than among SD vaccine recipients. Participants reporting feverishness 1 day after vaccination had mean fold rises in postvaccination hemagglutination inhibition titers that were 1.85-fold higher (95% confidence interval, 1.01–3.38) for A(H1N1) than in those who did not report feverishness. Conclusions: Some acute local reactions were more frequent after vaccination with MF59-adjuvanted and HD influenza vaccines, compared with SD inactivated influenza vaccine, whereas systemic symptoms occurred at similar frequencies in all groups. The association between feverishness and immunogenicity should be further investigated in a larger population. Clinical Trials Registration: NCT03330132.-
dc.languageeng-
dc.publisherOxford University Press. The Journal's web site is located at http://jid.oxfordjournals.org-
dc.relation.ispartofThe Journal of Infectious Diseases-
dc.rightsPre-print: Journal Title] ©: [year] [owner as specified on the article] Published by Oxford University Press [on behalf of xxxxxx]. All rights reserved. Pre-print (Once an article is published, preprint notice should be amended to): This is an electronic version of an article published in [include the complete citation information for the final version of the Article as published in the print edition of the Journal.] Post-print: This is a pre-copy-editing, author-produced PDF of an article accepted for publication in [insert journal title] following peer review. The definitive publisher-authenticated version [insert complete citation information here] is available online at: xxxxxxx [insert URL that the author will receive upon publication here].-
dc.subjectinfluenza-
dc.subjectvaccination-
dc.subjectreactogenicity-
dc.titleComparative reactogenicity of enhanced influenza vaccines in older adults-
dc.typeArticle-
dc.identifier.emailCowling, BJ: bcowling@hku.hk-
dc.identifier.emailNg, TWY: tiffnwy@hku.hk-
dc.identifier.emailPerera, RAPM: mahenp@hku.hk-
dc.identifier.emailLeung, NHL: nanleung@connect.hku.hk-
dc.identifier.emailChen, Y: echochen@hku.hk-
dc.identifier.emailSo, HC: haso9150@hku.hk-
dc.identifier.emailIp, DKM: dkmip@hku.hk-
dc.identifier.authorityCowling, BJ=rp01326-
dc.identifier.authorityPerera, RAPM=rp02500-
dc.identifier.authorityLeung, NHL=rp02637-
dc.identifier.authorityIp, DKM=rp00256-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1093/infdis/jiaa255-
dc.identifier.scopuseid_2-s2.0-85091126395-
dc.identifier.hkuros310749-
dc.identifier.volumeEpub 2020-05-14-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats